Sixty Degrees Pharmaceuticals

Contributing Author

Recent Articles by Sixty Degrees Pharmaceuticals

Sep-03	60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference SXTP GlobeNewswire
Aug-21	60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference SXTP GlobeNewswire
Aug-19	60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis SXTP GlobeNewswire
Aug-13	60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results SXTP GlobeNewswire
Jul-17	60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria SXTP GlobeNewswire
Jul-16	60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering SXTP GlobeNewswire
Jul-15	60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering SXTP GlobeNewswire
Jul-15	60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion SXTP GlobeNewswire
Jul-14	60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 SXTP GlobeNewswire
Jun-04	60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA (tafenoquine) 8-Count Bottle Format SXTP GlobeNewswire
Jun-03	Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals SXTP GlobeNewswire
May-15	60 Degrees Pharmaceuticals Announces First Quarter 2025 Results SXTP GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.